Connection

Sriharsha Tella to Humans

Back to Details
This is a "connection" page, showing publications Sriharsha Tella has written about Humans.
Sriharsha Tella
Connection Strength
0.305
Humans
  1. Comprehensive review of evaluation and management of cardiac paragangliomas. Heart. 2020 08; 106(16):1202-1210.
    View in: PubMed
    Score: 0.028
  2. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies. Chin Clin Oncol. 2021 Feb; 10(1):10.
    View in: PubMed
    Score: 0.028
  3. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol. 2020 05; 46(5):789-795.
    View in: PubMed
    Score: 0.027
  4. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020 01; 21(1):e29-e41.
    View in: PubMed
    Score: 0.027
  5. Association Between Hospital Volume, Therapy Types, and Overall Survival in Stage III and IV Cutaneous Malignant Melanoma. J Natl Compr Canc Netw. 2019 11 01; 17(11):1334-1342.
    View in: PubMed
    Score: 0.027
  6. Survival and prognostic factors in patients with pancreatic squamous cell carcinoma. Eur J Surg Oncol. 2019 Sep; 45(9):1700-1705.
    View in: PubMed
    Score: 0.026
  7. Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database. J Clin Endocrinol Metab. 2018 09 01; 103(9):3566-3573.
    View in: PubMed
    Score: 0.025
  8. Incidence, racial disparities and survival outcomes of mast cell malignancies: analysis from a national database. Leuk Lymphoma. 2018 09; 59(9):2254-2257.
    View in: PubMed
    Score: 0.024
  9. Association Between Iron-Deficiency Anemia and Hypophosphatemia. Am J Med. 2018 03; 131(3):e103-e104.
    View in: PubMed
    Score: 0.023
  10. Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):441-446.
    View in: PubMed
    Score: 0.006
  11. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
    View in: PubMed
    Score: 0.006
  12. Association Between Treatment Facility Volume, Therapy Types, and Overall Survival in Patients With Stage IIIA Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2019 03 01; 17(3):229-236.
    View in: PubMed
    Score: 0.006
  13. Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. HPB (Oxford). 2019 03; 21(3):379-386.
    View in: PubMed
    Score: 0.006
  14. Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. Leuk Lymphoma. 2019 02; 60(2):553-555.
    View in: PubMed
    Score: 0.006
  15. Fluoroquinolone-associated suicide. Eur J Intern Med. 2018 09; 55:e21-e22.
    View in: PubMed
    Score: 0.006
  16. A population-based analysis of second primary malignancies in T-cell neoplasms. Br J Haematol. 2019 04; 185(2):338-342.
    View in: PubMed
    Score: 0.006
  17. T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. Br J Haematol. 2019 04; 185(1):140-142.
    View in: PubMed
    Score: 0.006
  18. Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States. Clin Lymphoma Myeloma Leuk. 2018 07; 18(7):475-479.
    View in: PubMed
    Score: 0.006
  19. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer. Breast Cancer Res Treat. 2018 Aug; 170(3):677-685.
    View in: PubMed
    Score: 0.006
  20. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood. 2018 01 11; 131(2):265-268.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.